Physician profile
Charles Lin
NPI 1326042185
$19,073.15
in general payments reported to CMS, 2019-2025
38 companies · $867 in 2025
The $867 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,340 · 2020: $7,265 · 2021: $1,481 · 2022: $2,163 · 2023: $1,238 · 2024: $720 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.31 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11,466.98 | 2019-2021 | |
| Medtronic, INC. | $1,422.13 | 2021-2025 | Micra |
| Novartis Pharmaceuticals Corporation | $845.44 | 2019-2025 | |
| Pfizer INC. | $830.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $650.24 | 2019-2025 | Brilinta, Farxiga |
| Amgen INC. | $450.16 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $377.10 | 2019-2023 | Xarelto |
| Abbott Laboratories | $370.97 | 2019-2024 | Aveir, Tendril, Gallant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.66 | 2021-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $236.81 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $233.16 | 2019-2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $232.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.29 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $180.55 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $161.01 | 2019-2023 | Camzyos, Eliquis |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $126.67 | 2019 | |
| Boston Scientific Corporation | $117.96 | 2023-2024 | Ekosonic, Eluvia, Watchman Flx |
| Merck Sharp & Dohme LLC | $114.08 | 2021-2024 | Verquvo |
| Chiesi USA, INC. | $77.97 | 2019-2021 | |
| Abiomed | $73.32 | 2025 | |
| Esperion Therapeutics, INC. | $66.38 | 2021-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $58.65 | 2023-2025 | Onpattro |
| Astellas Pharma US INC | $55.84 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $54.41 | 2024 | Arcalyst |
| Vital Connect, INC | $44.87 | 2024-2025 | Vitalpatch Rtm |
| Lundbeck LLC | $44.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.67 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $43.66 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $36.05 | 2019 | |
| Edwards Lifesciences Corporation | $27.50 | 2025 | Sapien 3 Ultra Resilia |
| Preventice Services, LLC | $26.64 | 2021 | |
| Daiichi Sankyo INC. | $25.10 | 2025 | Injectafer |
| Altathera Pharmaceuticals LLC | $23.04 | 2023 | Sotalol Hydrochloride |
| Biotronik INC. | $20.95 | 2019 | |
| Stryker Corporation | $20.37 | 2025 | Flowtriever |
| Genzyme Corporation | $18.93 | 2023 | |
| Shockwave Medical, INC | $18.52 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Medtronic Vascular, INC. | $15.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.